STOCK TITAN

Azitra: Young Pharmaceuticals reports 5.22% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Azitra, Inc. shareholder Young Pharmaceuticals reported beneficial ownership of 316,300 common shares, or 5.22% of the outstanding class, as of November 16, 2026. It said the holding includes 238,500 shares purchased on the open market during the prior 60 days for approximately $198,992.70, plus 77,800 shares acquired earlier. The aggregate purchase price for all 316,300 shares was approximately $343,977.15, excluding brokerage commissions. Young Pharmaceuticals said it intends to communicate with Azitra’s board and management about opportunities to enhance stockholder value and may increase or decrease its position through open-market or private transactions depending on market conditions, other investment opportunities and share prices. Share counts and prices for transactions before October 26, 2026, reflect Azitra’s 1-for-10 reverse stock split effected that day.

Filing Explained

Young Pharmaceuticals reports no present plan or proposal for changes to Azitra’s capitalization, ownership or board structure, or a business combination or disposition, while saying it may consider such proposals in the future.

Beneficially owned shares 316,300 shares Young Pharmaceuticals' reported position as of November 16, 2026
Ownership percentage 5.22% Young Pharmaceuticals' reported beneficial ownership as of November 16, 2026
Shares outstanding 6,060,435 shares Denominator cited for the ownership percentage, based on Azitra's Form 10-Q filed November 12, 2026
Open-market purchases 238,500 shares Purchases reported for the prior 60 days
Purchase price of recent transactions Approximately $198,992.70 Amount paid for shares acquired in the transactions listed for the prior 60 days
Aggregate purchase price Approximately $343,977.15 Price for the 316,300 shares directly beneficially owned, excluding brokerage commissions
Earlier holdings 77,800 shares Acquired before the 60-day period; stated on a post-reverse-split basis
Reverse stock split 1-for-10 Azitra effected the reverse stock split on October 26, 2026
beneficial ownership regulatory
"beneficial ownership interest of approximately 5.22%"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole dispositive power regulatory
"Sole Dispositive Power 316,300.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
split-adjusted basis technical
"began trading on a split-adjusted basis the same day"
An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.
working capital financial
"using its working capital in open-market purchases"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
Reverse Stock Split technical
"effected a 1-for-10 reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AZTR shares does Young Pharmaceuticals own?

As of November 16, 2026, Young Pharmaceuticals reported beneficial ownership of 316,300 AZTR common shares, or approximately 5.22% of the outstanding shares.

How many AZTR shares did Young Pharmaceuticals buy in the past 60 days?

Young Pharmaceuticals reported open-market purchases of 238,500 shares during the past 60 days, for an approximate purchase price of $198,992.70.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





05479L302

(CUSIP Number)
John E. Kulesza
105 Progress Drive,
Wethersfield, CT, 06109
860-529-7919


Naz Zilkha
Dechert LLP, Three Bryant Park, 1095 Avenue of the Americas
New York, NY, 10036-6797
212-698-3599

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/06/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D


Young Pharmaceuticals, Inc.
Signature:/s/ John E. Kulesza
Name/Title:President
Date:11/16/2026

Keep reading